Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple ...
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Pyxis Oncology, Inc. (NASDAQ:PYXS), that sends out a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback